Theravance Biopharma News

Theravance Narrows Q1 Loss as Revenue Rises; Shares Rise After-hours

Theravance Biopharma (TBPH) Monday night reported a Q1 net loss of $0.24 per share, compared with $0.35 loss a year ago. Analysts polled by Capital IQ expected $0.25 loss. Revenue for the quarter ende

MT Newswires05:25

Theravance Biopharma Q1 2024 GAAP EPS $(0.24) Beats $(0.25) Estimate, Sales $14.503M Beat $13.963M Estimate

Theravance Biopharma (NASDAQ:TBPH) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.25) by 4 percent. The company reported quarterly sales of $14.503 mi

Benzinga04:13

Earnings Flash (TBPH) THERAVANCE BIOPHARMA Posts Q1 Revenue $14.5M, Vs. Street Est of $14M

04:10 PM EDT, 05/13/2024 (MT Newswires) -- Earnings Flash (TBPH) THERAVANCE BIOPHARMA Posts Q1 Revenue $14.5M, vs. Street Est of $14M

MT Newswires04:10

Press Release: Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire DUBLIN, May 13, 2024 -- Q1 2024 YUPELRI(R) (revefenacin) net sales of $55.2 milli

Dow Jones04:06

Theravance Biopharma 1Q Loss/Shr 24c >TBPH

Theravance Biopharma 1Q Loss/Shr 24c >TBPH

Dow Jones04:05

Theravance Biopharma to Participate in an Upcoming Investor Conference

Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at...

PR NewswireMay 9 18:00

Strong Week for Theravance Biopharma (NASDAQ:TBPH) Shareholders Doesn't Alleviate Pain of Five-year Loss

Theravance Biopharma, Inc. (NASDAQ:TBPH) shareholders should be happy to see the share price up 13% in the last week. But don't envy holders -- looking back over 5 years the returns have been reall

Simply Wall StMay 8 19:07

Theravance Biopharma(TBPH.US) 10% Shareholder Buys US$13.12 Million in Common Stock

$Theravance Biopharma(TBPH.US)$ 10% Shareholder Samaha Eli purchased 1.5 million shares of common stock on May 1, 2024 at an average price of $8.75 for a total value of $13.12 million.Source: Announce

Futu NewsMay 4 05:04

Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024

DUBLIN, April 29, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2024 financial results and provide a business update after market close on Monday, May 1

PR NewswireApr 29 18:00

Sector Update: Health Care Stocks Lower Friday Afternoon

Health care stocks were retreating Friday afternoon, with the NYSE Health Care Index falling 1.5% and the Health Care Select Sector SPDR Fund (XLV) dropping 1.6%. The iShares Biotechnology ETF (IBB) w

MT NewswiresApr 13 01:48

Theravance Biopharma Shares Rise After BTIG Starts Coverage at Buy

Theravance Biopharma (TBPH) shares climbed 8.3% in recent Friday trading after BTIG started its coverage with a buy rating and a price target of $21. Trading volume stood at more than 330,000 shares a

MT NewswiresApr 13 00:41

Veru, Theravance Biopharma, Adial Pharmaceuticals Among Healthcare Movers

Seeking AlphaApr 12 22:00

Theravance Biopharma (TBPH.US) was first covered by BTIG and given a buy rating, with a target price of $21.00.

Theravance Biopharma (TBPH.US) was first covered by BTIG and given a buy rating, with a target price of $21.00.

Zhitong FinanceApr 12 19:50

BTIG Initiates Coverage On Theravance Biopharma With Buy Rating, Announces Price Target of $21

BTIG analyst Julian Harrison initiates coverage on Theravance Biopharma with a Buy rating and announces Price Target of $21.

Analyst UpgradesApr 12 19:42

Theravance Biopharma Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/12/2024 135.16% BTIG → $21 Initiates Coverage On → Buy 08/08/2023 123.96% HC Wainwright & Co. → $20 Rei

BenzingaApr 12 19:36

Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (NOH) in Patients With Multiple System Atrophy (MSA) on May 23, 2024

Theravance Biopharma, Inc. (the "Company") (NASDAQ: TBPH) today announced it will host a virtual KOL event on Thursday, May 23, 2024 from 10:00 AM to ...

PR NewswireApr 10 18:00

Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?

Yahoo FinanceApr 3 23:30

A New Cause for Concern: Theravance Biopharma Adds a New Costs Risk

TipRanksMar 3 14:00

Theravance Biopharma: A Strong Buy on Underappreciated Cash Flow Potential and Strategic Milestones

TipRanksFeb 28 12:39

Theravance Biopharma: A Strong Buy on Robust Yupelri Sales and Promising Financial Milestones

TipRanksFeb 27 19:27